Haridarshan Patel

Haridarshan Patel

Auto-generated profile, based on publicly available information

Haridarshan Patel

Center for Observational Research, Amgen, Inc., Thousand Oaks, CA 91320, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
THToshifumi Hibi
Toshifumi Hibi
IKIsao Kamae
Isao Kamae
Philippe PintonPhilippe Pinton
Philippe Pinton
LULyann Ursos
Lyann Ursos
RIRyuichi Iwakiri
Ryuichi Iwakiri
HPHaridarshan Patel
Haridarshan Patel
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses.Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologicnaïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6–12) and maintenance (weeks 30–60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR).Results: At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics.Conclusions: All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase.

7 June 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
JBJohan Burisch
Johan Burisch
AHAilsa Hart
Ailsa Hart
ASAndreas Sturm
Andreas Sturm
CRChristine Rudolph
Christine Rudolph
RMRachael Meadows
Rachael Meadows
Alessandro ArmuzziAlessandro Armuzzi
Alessandro Armuzzi
Background: Understanding disease burden is imperative for improving inflammatory bowel disease (IBD) management. This real-world survey investigated residual disease burden and treatment satisfaction among European patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). Methods: The Adelphi Real World IBD Disease Specific Programme was a multinational, cross-sectional survey with retrospective collection of patient- and physician-reported data on disease burden and management. Between October 2020 and March 2021, participating gastroenterologists recruited their next 7 (UC) and 8 (CD) eligible patients and reported demographics and clinical characteristics. Patients completed symptom, health-related quality of life (HRQoL), and treatment satisfaction questionnaires. Data were adjusted for confounding variables and compared between patients in remission (clinical remission, endoscopic remission, or both) and not in remission. Results: Overall, 1040 patients (UC, n = 502; CD, n = 538) were included. Although most patients were in remission (UC, 66.1%; CD, 69.5%), most still reported symptoms (UC, 63.7%; CD, 74.1%), including flatulence, fatigue/tiredness, and abdominal pain/distension. In UC, there were no significant differences in the likelihood of experiencing 7 of 23 symptoms between patients in remission and not in remission. In CD, there was no significant difference in 19 of 23 symptoms between patients in remission and not in remission. Several symptoms were significantly associated with reduced HRQoL. HRQoL was significantly better among patients in remission than not in remission. Conclusions: Patients with IBD, both in remission and not in remission, experience residual symptoms that impair HRQoL. Comprehensive endpoints, incorporating HRQoL and patients’ perspectives, and improved treatments are needed to address residual disease and patients’ needs.

23 December 2019 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
HPHaridarshan Patel
Haridarshan Patel
GCGregory Sampang Calip
Gregory Sampang Calip
RDRobert J. DiDomenico
Robert J. DiDomenico
GSGlen T. Schumock
Glen T. Schumock
KSKatie J. Suda
Katie J. Suda
TLTodd A. Lee
Todd A. Lee

18 April 2023 in Current Medical Research and Opinion
Verified
Journal Article
Open access
JLJames O. Lindsay
James O. Lindsay
NPNils Picker
Nils Picker
DKDaniel Kromer
Daniel Kromer
MSMichael Smyth
Michael Smyth
HPHaridarshan Patel
Haridarshan Patel
Treatment of ulcerative colitis (UC) follows a stepwise approach that considers disease severity and disease activity. It has the goal of achieving and maintaining steroid-free remission and healing of the gut lining. Treatment options for UC include several conventional and advanced therapies. However, suboptimal response to treatment has been reported in previous observational studies. This results in treatment adjustments, such as therapy discontinuation, dose intensification and addition of conventional therapies, as well as lengthy concurrent use of corticosteroids. This retrospective chart review evaluated clinical practice data from eight clinics across the United Kingdom. This was done to assess rates of clinical remission and indicators of suboptimal response to advanced therapies among patients with UC. Analysis included data from January 2017 to September 2019. Nearly half of patients did not have clinical remission within one year after starting advanced therapies. Optimization of advanced therapies was often seen, even in patients in remission. The most common indicators of suboptimal therapy were therapy discontinuation, dose escalation of advanced therapy, and addition of conventional therapies. Our findings suggest that efficacy of advanced therapies to treat UC remains insufficient in clinical practice. Thus, there is a need for more effective treatment alternatives to achieve better outcomes for patients with UC.

8 May 2023 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
BBBernd Bokemeyer
Bernd Bokemeyer
NPNils Picker
Nils Picker
DKDaniel Kromer
Daniel Kromer
LRLudger Rosin
Ludger Rosin
HPHaridarshan Patel
Haridarshan Patel
Purpose: Many patients treated for ulcerative colitis (UC) do not achieve clinical remission. This real-world study assessed clinical remission and inadequate response rates among patients with UC in Germany treated with advanced therapies. Methods: This retrospective chart review included patients with UC newly initiating advanced (index) therapy (anti-TNFα agents, vedolizumab, tofacitinib) from January 2017–September 2019 (index date). Included patients had data for ≥ 12 months before (baseline period) and after the index date (follow-up period). Remission was defined as a partial Mayo score ≤ 1. Indicators of inadequate response were: index therapy discontinuation; therapy adjustments (index therapy dose escalation; augmentation with non-advanced therapies; corticosteroid [CS] use during maintenance therapy); CS dependency (use for ≥ 12 weeks); and UC-related hospitalisation, surgery or emergency department visit. Time to first remission and inadequate response were analyzed using Kaplan–Meier analyses. Results: Among 149 patients with UC (median age: 40 years), 96 (64.4%) were biologic-naïve and 42 (28.2%) received CS at the index date. Within 12 months, 52 patients (47.2%) were in remission; of these, 13 patients (25.0%) received ≥ 1 therapy adjustment. At 12 months, 55 patients (37.6%) had ≥ 1 indicator of an inadequate response. Median time to remission was longer among biologic-experienced vs biologic-naïve patients (24 vs 7 months; p = 0.012). Conclusion: Over half of the patients were not in clinical remission after 12 months and more than one-third experienced inadequate response. One-quarter of patients in remission required therapy adjustments. Patients with UC require therapies that are more effective than those currently available to achieve better treatment outcomes.

1 September 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
HPHaridarshan Patel
Haridarshan Patel
GCGregory S. Calip
Gregory S. Calip
RDRobert J. DiDomenico
Robert J. DiDomenico
GSGlen T. Schumock
Glen T. Schumock
KSKatie J. Suda
Katie J. Suda
TLTodd A. Lee
Todd A. Lee
Azithromycin is a widely prescribed antibiotic. More than 30 million prescriptions of azithromycin are dispensed every year in the United States.1 Compared with other macrolide antibiotics that carry some adverse cardiac risks, azithromycin was considered safest because of its lower arrhythmogenic activity.2